CDMO manufacturing APIs, HiPo/ADC compounds and its own Vitamin D analogues across India, Europe and China.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 |
| Reserves | 5.7k | 5.7k | 5.5k | 5.8k | 5.6k | 5.8k | 6.3k | 6.6k |
| Borrowings | 1.4k | 1.6k | 1.8k | 2.2k | 2.3k | 2.4k | 2.6k | 3.1k |
| Other Liabilities | 1.1k | 1.1k | 1.3k | 1.4k | 1.6k | 1.8k | 2.2k | 2.2k |
| Total Liabilities | 8.2k | 8.4k | 8.6k | 9.4k | 9.6k | 10.0k | 11.1k | 11.9k |
| AssetsFixed Assets | 5.7k | 5.7k | 5.8k | 6.2k | 6.7k | 7.1k | 8.0k | 8.4k |
| CWIP | 234 | 486 | 780 | 1.0k | 646 | 467 | 309 | 275 |
| Investments | 191 | 172 | 324 | 249 | 102 | 97 | 91 | 91 |
| Other Assets | 2.1k | 2.0k | 1.8k | 2.0k | 2.1k | 2.4k | 2.8k | 3.2k |
| Total Assets | 8.2k | 8.4k | 8.6k | 9.4k | 9.6k | 10.0k | 11.1k | 11.9k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 282 | 585 | 513 | 355 | 266 | 379 | 375 | 491 |
| Cash from Investing | -169 | -442 | -380 | -619 | -494 | -225 | -196 | -245 |
| Cash from Financing | -102 | -98 | -11 | 130 | 250 | -22 | -102 | 201 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -26 | 177 | 147 | -101 | -352 | 76 | 160 | 225 |
| FCF Margin | — | — | — | — | — | — | — | — |
For capital-heavy businesses (telecom, power, heavy manufacturing) reported profit ignores the cash needed just to stand still. We'd systematically overvalue it, so we don't show a number.
DCAL · CAPITAL_INTENSIVE
Guides on how to read this kind of business and the numbers that matter.